This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Original Article -
Dexamethasone suppresses DU145 cell proliferation and cell
cycle through inhibition of the extracellular signal-regulated
kinase 1/2 pathway and cyclin D1 expression
Qing-Zhen Gao1, Jia-Ju
Lu2, Zi-Dong Liu1, Hui
Zhang2, Shao-Mei Wang1, He
Xu1
1Friendship Nephrology and Blood Purification Center, Jinan City Central Hospital, Shandong University School of
Medicine, Shandong 250013, China
2Department of Urology, Shandong Provincial Hospital, Shandong 250021, China
Abstract
Aim: To determine the mechanisms of glucocorticoids in inhibiting advanced prostate cancer growth.
Methods: The cell proliferation and cell cycle of prostate cancer DU145 cells following dexamethasone treatment were determined
by proliferation assay and fluorescence-activated cell sorter. Western blot analysis was carried out to evaluate the
effects of dexamethasone on phosphorylation of extracellular signal-regulated kinase (ERK)1/2 and expression of
cyclin D1 in DU145 cells with or without glucocorticoid receptor (GR) antagonist RU486. Reverse
transcription_polymerase chain reaction verified the expression of GR mRNA in DU145 cells.
Results: Dexamethasone significantly inhibited DU145 cell proliferation at the
G0/G1 phase. Western blot analysis showed a dramatic reduction of
ERK1/2 activity and cyclin D1 expression in dexamethasone-treated cells. The decreased phosphorylation of
ERK1/2 in dexamethasone-treated cells was attenuated by GR blockade. Additionally, the effects of dexamethasone in inhibiting
cyclin D1 expression were altered by GR blockade.
Conclusion: Dexamethasone suppresses DU145 cell
proliferation and cell cycle, and the underlying mechanisms are through the inhibition of phosphorylation of ERK1/2 and cyclin
D1 expression. The inhibition of ERK1/2 phosphorylation and cyclin D1 expression is attenuated by GR blockade,
suggesting that GR regulates ERK1/2 and cyclin D1 pathways. These observations suggest that
dexamethasone has a potential clinical application in prostate cancer
therapy. (Asian J Androl 2008 Jul; 10: 635_641)
Keywords: dexamethasone; prostate cancer; extracellular signal-regulated kinase 1/2; cell cycle
Correspondence to: Zi-Dong Liu, MD, PhD, Friendship
Nephrology Center and Blood Purification Center, Jinan City Central Hospital,
Shandong University School of Medicine, Jinan 250013, China.
Tel: +86-531-8569-5759 Fax: +86-531-8696-8858
E-mail: jfbpc@public.jn.sd.cn
Received 2007-05-20 Accepted 2007-08-23
DOI: 10.1111/j.1745-7262.2008.00352.x
1 Introduction
The growth of prostate cancer during its initial phase
is androgen-dependent. However, the progress of
cancer from androgen-dependent to androgen-independent
has been observed in prostate cancer patients [1]. Indeed,
patients with relapsed cancer are refractory to current
hormonal therapy, and the outcome is usually poor due
to the lack of effective therapies [2].
The growth of cells is regulated by multiple
intracellular signaling pathways [3, 4]. Mitogen-activated
protein kinases play an important role in regulating cell
responses, and this superfamily includes extracellular
signal-regulated kinase (ERK)1/2, c-Jun NH2-terminal
kinase, and the p38 protein kinase [5]. The
phosphorylation of ERK1/2 followed by translocation to the nucleus
is critical for initiation of cells from the
G1 to S phase resulting in cell growth/proliferation [6]. Other studies
have suggested that the activation of ERK1/2 results in
cyclin D1 upregulation [7], and shown the links between
overexpression of cyclin D1 and primary or
tumor-derived prostate cancer cells [8]. The activity of ERK1/2
pathway plays important roles during prostate cancer
development. The ERK1/2 activation is directly related
to poor histological and prognostic features [9], and
constitutive activation of the ERK1/2 pathway can promote
androgen hypersensitivity in prostate cancer cells
[10].
Glucocorticoids have been used to treat cancer due
to their overall palliative effects. Recent studies have
observed benefits in combined use of glucocorticoids
with calcitriol, somatostatin analog and
131I in advanced prostate cancer patients [11_13].
In vivo studies have shown growth inhibition by glucocorticoids is through
anti-angiogenetic effects or inhibition of
lymphangioge-nesis [14, 15]. Earlier studies suggested a possible role
of nuclear factor-κB/interleukin-6 signaling and
transforming growth factor (TGF)-β in the growth inhibitory
effects of dexamethasone [16, 17]. Considering ERK1/2
effects and its high activity during the progress of
prostate cancer, we have hypothesized that glucocorticoids
might inhibit growth of prostate cancer cells by altering
the activity of the ERK1/2 pathway and cyclin D1 expression. To test this hypothesis, we have chosen an
advanced prostate cancer cell line, DU145, that has high
ERK1/2 pathway activity, and used dexamethasone to
interfere with cell growth. We detected the cell
proliferation, cell cycle, ERK1/2 pathway activity, and cyclin D1
expression after dexamethasone treatment.
2 Materials and methods
2.1 Reagents and antibodies
Dexamethasone and RU486 were purchased from
Sigma (St. Louis, MO, USA), and dissolved in 100% ethanol. Rabbit polyclonal antibodies specific
to human phospho-ERK1/2 and total ERK1/2, and monoclonal
antibodies specific for cyclin D1 and β-actin, and isotype
control immunoglobulin (Ig) were obtained from R&D
Systems (Minneapolis, MN, USA). Secondary goat
anti-rabbit IgG antibody and isotype Ig were obtained from
Shenergy BioScience (Shanghai, China).
2.2 Cell culture
Prostate cancer cell line DU145, characterized with
an androgen-independent phenotype, was obtained from
Shanghai Institutes for Biological Sciences (Shanghai,
China). Primary DU145 cultures and subcultures were
carried out in Ham's F12K culture medium (Gibco, New
York, NY, USA) supplemented with 10% fetal bovine serum and
antibiotics.
2.3 Reverse transcription-polymerase chain reaction
(RT-PCR)
The glucocorticoid receptor (GR) protein expression in
DU145 cells has been shown in earlier reports [18]. In this
study, RT-PCR was carried out to verify the expression of
GR mRNA in DU145 cells. Briefly, normal untreated DU145
cells were collected from cultures, and mRNA was isolated
by the acid guanidine-phenol-chloroform method. Complementary DNA (cDNA) was synthesized using an
RT-PCR kit (Shenergy BioScience, Shanghai, CHina).
RT-PCR was carried out using GR-specific primers (sense
5'-TCCCTTTCTCAACAGCAGGAT-3' and antisense
5'-CAATCATTCCTTCCAGCACAT-3'). The 371 bp cDNA
product was separated on a 2% agarose gel and
visualized by staining with ethidium bromide. A
cell line of JAR was used as a negative control.
2.4 Cell proliferation assays
DU145 cells were collected from cultures and diluted to
104 cells/mL with culture medium. A total of
104 cells was added into 100 mm culture dishes and
incubated overnight until cells adhered to the bottom of
the dishes. Cells were washed to remove non-adhered
cells then treated with dexamethasone at different
concentrations. To determine whether the inhibitory
effects were GR dependent, RU486, a GR antagonist,
was used to block GR. RU486 was added to dexamethasone-treated cells at different concentrations to
measure its antagonist effects. An equal volume of ethanol
vehicle was added to cells and used as a control.
Proliferative cell numbers were determined by a hemacytometer.
All experiments were repeated at least three times with
equivalent results.
2.5 Cell cycle analysis
DU145 cells were harvested after a 3-day incubation
with ethanol carrier or dexamethasone
(2 × 10-7 mol/L) with or without RU486
(2 × 10-7 mol/L). Cells were
stained with staining buffer containing propidium iodide
(50 µg/mL), RNAse A (100 Kunitz units/mL),
then washed twice with phosphate-buffered saline. The cells
were re-suspended in buffer, and the DNA content was
detected by a fluorescence-activated cell sorter (Becton
Dickinson, San Jose, CA, USA) to determine DNA state
after final wash. ModFit software version 5.11 (Verity
Software House Inc., Topsham, ME, USA) was used to
evaluate cell cycle.
2.6 Western blot analysis
Cells were collected from cultures with or without
treatment, and whole cell lysates were prepared using
lysis buffer (0.5% NP-40, 10% glycerol, 50 mmol/L
Tris-HCl [pH 7.5], 0.3 mmol/L sodium orthovanadate,
100 mmol/L NaCl, and 1 mmol/L
dithiothreitol). Protein concentrations were determined by bicinchoninic acid
assay. Equal amounts of protein lysates (50 µg) were
loaded and electrophoretically separated on sodium
dodecylsulfate-polyacrylamide gels. Proteins were
transferred electrophoretically from gels to nitrocellulose
membranes. Membranes were washed with Tris-Buffered Saline Tween-20 (TBST), and incubated with
TBST containing 5% non-fat dry milk to block non-specific
antibody binding followed by incubation with various
primary antibodies at 4ºC for 12 h. Membranes were
washed with TBST then immunoblotted with secondary
antibodies at room temperature for 60 min. Detection of
ERK1/2 and cyclin D1 proteins was carried out in the
dark using enhanced chemiluminescence (Santa Cruz Biotechnology, Santa Cruz, CA, USA) according to
the instructions provided by the manufacturer. The
semiquantification of protein expression was determined
by an imaging system (Bio-Rad, Hercules, CA, USA).
2.7 Statistical analysis
The statistical significance of the results was
analyzed by paired t-test, and P < 0.05 was considered to
be statistically significant. All statistical analyses were
carried out with the use of SPSS software version 11.0
(SPSS, Chicago, IL, USA). All statistical tests were
two-sided.
3 Results
3.1 GR mRNA expression in DU145 cells
We have hypothesized that the effects of
dexamethasone in inhibiting prostate cancer cell proliferation are GR
dependent. The initial focus of this in
vitro study was to verify the expression of the GR gene in DU145 cells. As
shown in Figure 1, RT-PCR showed the expression of
GR-specific mRNA in prostate cancer cell DU145.
3.2 Dexamethasone inhibits DU145 cell proliferation
The proliferation of DU145 cells with or without
dexamethasone was determined by a cell proliferation assay.
Cells without treatment or treated with control ethanol
carrier showed dramatic proliferation beginning after
2 days of incubation, and reached high levels after 6 days
of culture. The proliferation of DU145 cells in the
presence of dexamethasone was dramatically inhibited in a
dose-dependent manner after incubation for 6 days when
compared to control groups (Figure 2A). But the cell
viability evaluated by Trypan Blue exclusion method did
not indicate increased cell death when compared to
untreated cells. Cells treated with both dexamethasone and
RU486 showed that GR blockade dramatically reduced
the inhibitory effects of dexamethasone in preventing
cancer cell proliferation (Figure 2).
3.3 Dexamethasone induces cell cycle arrest
To determine the effects of dexamethasone in
inhi-biting the cell cycle during proliferation, cells treated with
or without dexamethasone were collected from 3-day
cultures, and the cellular DNA content was measured by
fluorescence-activated cell sorting. Table 1 summarizes
the inhibitory effects of dexamethasone on the DU145
cell cycle. The inhibitory effects of dexamethasone on
the cell cycle were blocked by GR antagonist RU486.
3.4 Dexamethasone inhibits phosphorylation of
ERK1/2 and expression
To study the underlying mechanisms, the total and
phospho-ERK1/2 in DU145 cells treated with or without
dexamethasone were evaluated by Western blot analysis.
Untreated cells indicated expression of ERK1/2 proteins
and constant phosphorylation of ERK1/2 between 1 and
3 days of cultures. Dexamethasone gradually diminished
ERK1/2 activity at 24, 48, and 72 h after treatment (Figure
3). The most important finding was that, although the
ERK1/2 pathway was consistent active and total
ERK1/2 expression was not affected by dexamethasone treatment
(Figure 4A), phosphorylation of ERK1/2 in cells was
dramatically suppressed after 3 days of incubation (Figure
4B). The semiquantification of ERK1/2 phosphorylation
showed a 55.1% ± 10.7% reduction in cells treated with
dexamethasone when compared with untreated cells (Figure 4C). Additionally, GR blockade attenuated the
effects of dexamethasone in inhibiting phosphorylation
of ERK1/2 in DU145 cells (Figure 4B, C).
3.5 Dexamethasone inhibits cyclin D1 expression
We first examined the expression of cyclin D1
protein during DU145 cancer proliferation, and a persistent
expression of cyclin D1 protein in DU145 cells was
observed. Dexamethasone gradually diminished cyclin
D1 expression at 24, 48, and 72 h after treatment (Figure
3). As shown in Figure 5, dexamethasone dramatically
reduced cyclin D1 expression in DU145 cells after 3 days
of culture. The cyclin D1 expression as determined by
semiquantification was decreased by 82.6% ± 5.5% when
compared with untreated cells. Additionally, GR
blockade altered the effects of dexamethasone on DU145 cells,
and the reduction of cyclin D1 protein expression was
attenuated in dexamethasone-treated cells.
4 Discussion
One very limited report has shown that cortisol and
cortisone promote growth activation through mutant androgen receptor in some patients [19]. However,
increasing evidence has suggested that dexamethasone can
provide therapeutic effects in patients with prostate
cancer, particularly hormone refractory carcinoma
[11_13]. Indeed, DU145 cells lack androgen receptors.
Nevertheless, the mechanisms of dexamethasone that
block cancer cell proliferation were unclear. The
phosphorylation of ERK1/2 followed by translocation to the
nucleus has been shown to be critical for initiation of
cells from the G1 to S phase resulting in cell
growth/proliferation [8]. Activation of ERK1/2 leads to upregulation
of cyclin D1 [7]. We have used the advanced prostate
cancer cell line DU145 to determine the effects of
dexamethasone in blocking cancer proliferation, and to
determine whether the inhibitory effects are ERK1/2 pathway
dependent. Our data shows that dexamethasone can
dramatically inhibit DU145 cell proliferation without increased
cell death, and the majority of DU145 cells remained at
the G0/G1 phase in the presence of
dexamethasone, suggesting its direct antiproliferative effects to prostate
cancer cells.
We carried out a mechanistic study to determine the
mechanisms of dexamethasone in inhibiting the ERK1/2
pathway. The phosphorylation of ERK1/2 protein and
total protein was evaluated following treatment with
dexamethasone. We found that the activated form of
ERK1/2 was markedly reduced after dexamethasone treatment and
the levels of total ERK1/2 remained unchanged, suggesting that dexamethasone alters
phosphorylation of ERK1/2 protein without suppressing total
ERK1/2 protein expression. Additionally, cyclin D1
expression in DU145 cells treated with dexamethasone is
also dramatically reduced. These findings suggest that
the inhibitory effects of dexamethasone on DU145
cancer cells are associated with ERK and cyclin D1 pathways.
We also investigated whether the effects of
dexame-thasone in inhibiting prostate cancer cell proliferation are
GR-dependent. The DU145 cells express the GR gene,
and the ligation of GR leads to the suppression of
phosphorylation of ERK1/2 proteins. The GR blockade with
GR antagonist RU486 dramatically attenuates the
inhibitory effects of dexamethasone not only on cell
proliferation but also phosphorylation of ERK1/2 proteins. These
observations indicate that the inhibitory effects of
dexamethasone on phosphorylation of ERK1/2 proteins are
through the GR pathway. One interesting observation is
that there is a marked reduction of cyclin D1 expression
in dexamethasone-treated cancer cells. Additionally, GR
blockade displays a dramatic effect in altering the
inhibitory effects of dexamethasone on cyclin D1 expression
in DU145 cells. These findings suggest that pathways
for the inhibition of DU145 cell proliferation by
dexamethasone are dependent on its interaction with GR
followed by suppression of ERK1/2 phosphorylation and
decreased cyclin D1 expression leading to inhibition of
cell proliferation.
It has been elucidated that glucocorticoid has
genomic and non-genomic actions with different features.
Non-genomic action occurs in seconds or minutes, whereas genomic action occurs in hours or days. Both
genomic and non-genomic actions can affect phosphorylation of ERK1/2 and expression of cyclin D1. Our
study found that ERK1/2 activity and cyclin D1
expression gradually diminished over 3 days following
treatment with dexamethasone. This finding suggests that
dexamethasone suppresses DU145 cell proliferation through genomic action.
It is believed that intracellular signaling pathways,
such as the ERK1/2 pathway, and cyclin D1 expression
play critical roles in regulating cell proliferation/apoptosis
and in the development of prostate cancer. This study
clearly shows that dexamethasone suppresses
phosphorylation of ERK1/2 and cyclin D1 expression in DU145
cells, leading to reduced cell proliferation. Both ERK1/2
and cyclin D1 pathways contribute to the effect of
dexamethasone in inhibiting cancer cell
proliferation, and the inhibition of the ERK1/2 pathway and cyclin D1
expression by dexamethasone is GR-dependent. These
observations suggest that dexamethasone might have a
potential clinical application in prostate cancer therapy.
References
1 Altuwaijri S, Wu CC, Niu YJ, Mizokami A, Chang HC, Chang
C. Expression of human AR cDNA driven by its own
promoter results in mild promotion, but not suppression, of
growth in human prostate cancer PC-3 cells. Asian J Androl
2007; 9: 181_8.
2 He QJ, Yang B, Lou YJ, Fang RY. Contragestazol (DL111-IT)
inhibits proliferation of human androgen-independent
prostate cancer cell line PC3 in vitro and
in vivo. Asian J Androl 2005; 7: 389_93.
3 Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg
ME. Cell survival promoted by the Ras-MAPK signaling
pathway by transcription-dependent and -independent
mechanisms. Science 1999; 286: 1358_62.
4 Clark JA, Black AR, Leontieva OV, Frey MR, Pysz MA,
Kunneva L, et al. Involvement of the ERK signaling cascade in
protein kinase C-mediated cell cycle arrest in intestinal
epithelial cells. J Biol Chem 2004; 279: 9233_47.
5 Davis RJ. MAPKs: new JNK expands the group. Trends
Biochem Sci 1994; 19: 470_3.
6 Brondello JM, McKenzie FR, Sun H, Tonks NK, Pouysségur
J. Constitutive MAP kinase phosphatase (MKP-1)
expression blocks G1 specific gene transcription and S-phase entry
in fibroblasts. Oncogene 1995; 10: 1895_904.
7 Nupponen N, Visakorpi T. Molecular biology of progression
of prostate cancer. Eur Urol 1999; 35: 351_4.
8 Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H,
Gasser TC, et al. Survey of gene amplifications during prostate
cancer progression by high-throughput fluorescence
in situ hybridization on tissue microarrays. Cancer Res 1999; 59: 803_6.
9 Gioeli D, Mandell JW, Petroni GR, Frierson HF, Weber MJ.
Activation of mitogen-activated protein kinase associated with
prostate cancer progression. Cancer Res 1999; 59: 279_84.
10 Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ.
Constitutive activation of the Ras/mitogen-activated protein
kinase signaling pathway promotes androgen
hypersensiti-vity in LNCaP prostate cancer cells. Cancer Res 2003; 63:
1981_9.
11 Johnson CS, Hershberger PA, Bernardi RJ, Mcguire TF, Trump
DL. Vitamin D receptor: a potential target for intervention.
Urology 2002; 60 (3 Suppl 1): 123_30; discussion 130_1.
12 Koutsilieris M, Mitsiades CS, Bogdanos J, Dimopoulos T,
Karamanolakis D, Milathianakis C,
et al. Combination of somatostatin analog, dexamethasone, and standard androgen
ablation therapy in stage D3 prostate cancer patients with bone
metastases. Clin Cancer Res 2004; 10: 4398_405.
13 Scholz IV, Cengic N, Göke B, Morris JC, Spitzweg C.
Dexamethasone enhances the cytotoxic effect of radioiodine
therapy in prostate cancer cells expressing the sodium iodide
symporter. J Clin Endocrinol Metab 2004; 89:
1108_16.
14 Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K.
Glucocorticoids suppress tumor angiogenesis and
in vivo growth of prostate cancer cells. Clin Cancer Res 2006; 12: 3003_9.
15 Yano A, Fujii Y, Iwai A, Kawakami S, Kageyama Y, Kihara K.
Glucocorticoids suppress tumor lymphangiogenesis of
prostate cancer cells. Clin Cancer Res 2006; 12: 6012_7.
16 Nishimura K, Nonomura N, Satoh E, Harada Y, Nakayama M,
Tokizane T, et al. Potential mechanism for the effects of
dexamethasone on growth of androgen-independent prostate
cancer. J Natl Cancer Inst 2001; 93: 1739_46.
17 Li Z, Chen Y, Cao D, Wang Y, Chen G, Zhang S,
et al. Glucocorticoid up-regulates transforming growth
factor-β (TGF-β) type II receptor and enhances
TGF-β signaling in human prostate cancer PC-3 cells. Endocrinology 2006; 147:
5259_67.
18 Dondi D, Maggi R, Scaccianoce E, Martini L, Motta M, Poletti
A. Expression and role of functional glucocorticoid receptors
in the human androgen-independent prostate cancer cell line,
DU145. J Mol Endocrinol 2001; 26: 185_91.
19 Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM,
Peehl DM, et al. Glucocorticoids can promote
androgen-independent growth of prostate cancer cells through a mutated
androgen receptor. Nat Med 2000; 6: 703_6.
|